Ecolab
ECL · What the business does, what can go wrong, and how options sellers approach it
What it does
Ecolab provides water, hygiene and infection prevention products and services to businesses. Its customers include hotels, restaurants, hospitals, food and beverage processors, manufacturers and other industrial sites.
The product range covers cleaning and sanitizing chemicals, dishwashing and laundry systems, water treatment programs, pest elimination and food safety tools. Much of the offering is delivered with on-site service and dosing equipment, not just sold as a bottle of chemicals.
How it makes money
Ecolab sells consumable products and services that customers use up and reorder. Many relationships are ongoing, with service representatives visiting sites, maintaining equipment and tracking results.
The pitch is often about outcomes: cleaner facilities, safer food, lower water and energy use. Because the products are tied to daily operations and compliance, customers tend to reorder regularly. Revenue also comes from equipment, monitoring and data tools that support the recurring business.
Why investors own it
Investors often view Ecolab as a business with relatively stable, recurring demand. Its demand is linked to hygiene, safety and water conservation, which are ongoing needs in many economic conditions. It has a long dividend record and a broad customer base across industries and regions.
Its service network and customer relationships can be hard for smaller rivals to match.
What can go wrong
- Raw material and energy costs can rise faster than the company can raise prices.
- Travel, hospitality and industrial slowdowns can reduce volumes.
- Competitors, including large chemical firms and local specialists, can pressure prices.
- Currency swings affect results because the company operates globally.
- Acquisitions may be harder to integrate than expected.
- Regulation of chemicals, water use and food safety can raise compliance costs.
What to watch
- Organic sales growth by segment
- Operating margin trends
- Raw material and delivered product costs
- Pricing versus volume
- Hospitality and institutional customer activity
- Free cash flow and dividend coverage
- Management commentary on acquisitions and integration
Options income angle
Options on ECL are generally available across a range of strikes and expirations, though they are usually less active than those on the largest mega-cap stocks. Bid-ask spreads can be wider on less popular strikes.
Implied volatility tends to rise around quarterly earnings and guidance updates, and during broad market stress. It is often moderate for a stock with this kind of recurring business.
One caution: a sharp move after earnings can quickly overwhelm the small premium collected on a short option. Check the earnings date before selling premium.
What the latest 10-K says
A plain-English read of the Risk Factors and Management's Discussion in the 10-K for the year ended December 31, 2025, filed February 23, 2026. Figures are as the filing reports them. Read the filing on SEC.gov
The filing in brief
Ecolab reported record sales, operating margin, adjusted earnings per share and free cash flow for 2025. Price increases and productivity drove the gains, and 2025 included the $1.6 billion Ovivo Electronics purchase for semiconductor water technology. Reported profit slipped because 2024 had a large one-time gain, and the company expanded its One Ecolab restructuring program in February 2026.
How the business did
- Reported sales rose 2% to $16.1 billion. Organic sales (growth excluding currency swings, acquisitions and sales of businesses) rose 3%, with volume up 1% and price up 2%.
- Reported operating income fell 2% to $2.7 billion because 2024 included a gain on selling the global surgical solutions business. Adjusted operating income, which strips out one-time items and Ovivo Electronics, rose 11%. Reported diluted EPS was $7.28 against $7.37, while adjusted diluted EPS rose 13% to $7.53.
- Organic sales grew 6% in Global Pest Elimination and 5% in Global Life Sciences. Global Institutional & Specialty grew 3% and Global Water grew 2%. Within Water, Paper organic sales declined 3% on soft customer production, while high-tech work for data centers and microelectronics grew at double-digit rates.
- Operating cash flow was $3.0 billion, against $2.8 billion in 2024. Dividends declared were $2.68 per share, and the quarterly dividend was raised 12% to $0.73 per share, the 34th consecutive annual increase.
Risks specific to this company
- Debt: Indebtedness was approximately $8.2 billion, with approximately $1.5 billion at floating rates. A one percentage point rise in the average rate on that floating debt would add approximately $15 million per year of interest expense.
- Acquired assets: Goodwill (the premium paid above the value of acquired assets) was $9.2 billion, tied partly to the Nalco, Purolite and Ovivo Electronics deals. A write-down would hit earnings, though the filing says no goodwill impairment has occurred.
- Overseas exposure: About 47% of 2025 net sales came from outside the United States, across more than 170 countries. New tariffs and retaliatory tariffs in 2025 created uncertainty, and Argentina, Turkey and Egypt are treated as highly inflationary.
- ChampionX split-off: Ecolab may owe indemnification to ChampionX under the 2020 separation agreements. If the split-off were found taxable, Ecolab and its stockholders could face significant tax liabilities, and Ecolab has no IRS ruling on the matter.
- Restructuring and systems: Execution risk covers the One Ecolab program, a multi-year ERP (internal business software) upgrade, and supply chain investments to add Life Sciences capacity.
- Gulf Coast: The region supplies raw materials and is a key customer base for the Light & Heavy segment. Hurricanes or freezes could disrupt both.
What management is watching
- The expanded One Ecolab program is expected to cost $334 million in restructuring and $91 million in special charges by the end of 2027, mostly cash severance. Management targets annualized cost savings of $325 million by 2027 and reports $119 million delivered so far.
- Ovivo Electronics sits in Light & Heavy and adds exposure to semiconductor manufacturing. The company says it will keep pursuing acquisitions and capital investments, with capital expenditures of $1.0 billion in 2025.
- Management expects operating cash flow to remain strong and to fund debt repayments, investment, dividends, repurchases and possible acquisitions.
- The company points investors to adjusted and organic measures, free cash flow, and net debt to EBITDA, which was 2.0 at year end.
- Management says it aims to hold "A" range credit ratings, which were A-, A3 and A- from the three agencies, and reports compliance with its debt covenants.
What the latest 10-Q says
A plain-English read of Management's Discussion (and any new or changed risk factors) in the 10-Q for the quarter ended September 30, 2026, filed October 29, 2026. Figures are as the filing reports them. Read the filing on SEC.gov
The quarter in brief
Ecolab's third-quarter reported net sales rose 13% to $4,694.8 million, and organic sales (growth that strips out acquisitions, divestitures and currency swings) rose 7%. Adjusted diluted EPS increased 5% to $2.18, while reported diluted EPS decreased 5% to $1.95. Acquisition costs and much higher interest expense from financing the CoolIT Systems and Ovivo Electronics deals weighed on the reported figures.
How the business did
- Sales: The 7% organic gain came from 2% volume and 5% pricing. For the nine months, reported net sales were $13,176.3 million, up 11%, and organic sales rose 5%.
- Profit: Reported operating income increased 7% to $810.5 million, and adjusted operating income (which excludes one-off "special" charges) increased 14%. Net income attributable to Ecolab decreased 6% to $551.3 million. Special charges were $82.9 million, against $26.5 million a year earlier. Net interest expense was $124.8 million, against $55.3 million.
- Segments: Global Water organic sales rose 9% to $2,239.4 million, led by High-Tech, up 63% on new business in microelectronics and data centers. Global Life Sciences accelerated 17% to $215.8 million. Global Pest Elimination rose 8% and Global Institutional & Specialty rose 3%. Organic gross margin was 44.9%, against 44.8%, as pricing offset higher commodity costs.
- Cash and capital: Cash from operations for the nine months was $1,939.1 million, against $1,862.5 million, after one-time incentive payments of $200 million tied to the two acquisitions. Cash used for investing was $5,621.1 million, mostly for CoolIT Systems, and the company issued $5 billion of long-term debt. Share repurchases were $672 million and dividends were $629 million. Net debt to EBITDA (a leverage ratio using earnings before interest, taxes, depreciation and amortization) was 3.1, against 2.0 at December 31, 2025.
What management is watching
- Energy and raw material costs: Management points to war in the Middle East as a driver of volatile energy prices and higher costs across its supply chain. An energy surcharge began in the second quarter of 2026. Management expects pricing actions, volume growth and cost savings to offset the pressure.
- One Ecolab restructuring: Management anticipates total restructuring costs of $328 million by the end of 2027, with estimated annualized cost savings of $325 million by 2027. The program has delivered $217 million of cumulative savings so far.
- Spending and funding: Capital expenditures were $902 million for the nine months. Management says it expects operating cash flow to remain strong and expects to fund its needs from that cash and, as needed, additional borrowing. Notes payable and long-term debt due within one year were $1,277 million.
- Measures it highlights: Management directs investors to organic, adjusted and fixed currency figures, which remove the effects of acquisitions, one-off charges and exchange rates, and to the net debt to EBITDA ratio.
Follow ECL in Kortex
The Kortex app shows ECL's price, options chain and IV rank, and answers your questions from live market data and SEC filings.
Free to download.
Learn the strategies
More stock briefs
For education only, not financial advice. Options involve risk and are not suitable for every investor.